Aadi Bioscience Inc
(STU:3350)
€
1.8
0.08 (4.65%)
Market Cap: 45.40 Mil
Enterprise Value: -24.00 Mil
PE Ratio: 0
PB Ratio: 0.64
GF Score: 41/100 Aadi Bioscience Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript
May 30, 2023 / 03:30PM GMT
Release Date Price:
€7.05
Boris Peaker
TD Cowen - Analyst
Thank you, everyone, for joining us. I'm Boris Peaker. I'm one of the biotech analysts here at TD Cowen. It's my pleasure to host Scott Giacobello, the CEO of Aadi Bioscience. Scott, thanks for joining us.
Scott Giacobello
Aadi Bioscience, Inc. - CEO, Interim President, CFO, & Treasurer
Thanks, Boris, great to be here today.
Questions & Answers
Boris Peaker
TD Cowen - Analyst
So Aadi has an approved drug called FYARRO, which is in late-stage clinical development for a range of tumor-agnostic indications as well as, as I mentioned, approval for an orphan indication in oncology. Can you give us a little background, Scott, on the actual mechanism of action of FYARRO and where the drug came from?
Scott Giacobello
Aadi Bioscience, Inc. - CEO, Interim President, CFO, & Treasurer
Yes, sure, absolutely. So the drug -- actually, our founder, Neil Desai, was originally with Abraxis and actually licensed the technology out of
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot